Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

balstilimab (AGEN2034)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Agenus, Betta Pharma, Recepta

Drug class:

PD1 inhibitor

Related drugs:

‹

pembrolizumab (726)

nivolumab (607)

sintilimab (115)

toripalimab-tpzi (88)

camrelizumab (85)

tislelizumab (84)

dostarlimab-gxly (42)

cemiplimab-rwlc (29)

zimberelimab (20)

pucotenlimab (12)

cadonilimab (10)

serplulimab (6)

retifanlimab-dlwr (6)

PF-06801591 (6)

JNJ-63723283 (5)

nivolumab/relatlimab (4)

geptanolimab (3)

CMAB 819 (nivolumab biosimilar) (0)

EBV-specific anti-PD1 TCR-T cells (0)

enlonstobart (0)

prolgolimab (0)

NY-ESO-1 TCR-T cell therapy (0)

prolgolimab/nurulimab (0)

PD-1 knockout engineered T cells (0)

PF-07209960 (0)

Undisclosed anti PD-1 mAb (0)

anti-PD-1 antibody (0)

›

No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	AGEN2034 + UGN-301 Sensitive: B - Late Trials AGEN2034 + UGN-301 Sensitive : B	AGEN2034 + UGN-301 Sensitive: B - Late Trials AGEN2034 + UGN-301 Sensitive : B
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	AGEN2034 Sensitive: B - Late Trials AGEN2034 Sensitive : B	AGEN2034 Sensitive: B - Late Trials AGEN2034 Sensitive : B
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	AGEN2034 + AGEN1181 Sensitive: B - Late Trials AGEN2034 + AGEN1181 Sensitive : B	AGEN2034 + AGEN1181 Sensitive: B - Late Trials AGEN2034 + AGEN1181 Sensitive : B
PD-L1 expression	Cervical Cancer	PD-L1 expression	Cervical Cancer	AGEN2034 Sensitive: C2 – Inclusion Criteria AGEN2034 Sensitive : C2	AGEN2034 Sensitive: C2 – Inclusion Criteria AGEN2034 Sensitive : C2
PD-L1 negative	Cervical Cancer	PD-L1 negative	Cervical Cancer	AGEN2034 Sensitive: C3 – Early Trials AGEN2034 Sensitive : C3	AGEN2034 Sensitive: C3 – Early Trials AGEN2034 Sensitive : C3
PD-L1 expression	Cervical Cancer	PD-L1 expression	Cervical Cancer	AGEN2034 + UGN-301 Sensitive: C3 – Early Trials AGEN2034 + UGN-301 Sensitive : C3	AGEN2034 + UGN-301 Sensitive: C3 – Early Trials AGEN2034 + UGN-301 Sensitive : C3
PD-L1 expression	Colorectal Cancer	PD-L1 expression	Colorectal Cancer	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials AGEN2034 + AGEN1181 Sensitive : C3	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials AGEN2034 + AGEN1181 Sensitive : C3
NRAS mutation	Colorectal Cancer	NRAS mutation	Colorectal Cancer	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials AGEN2034 + AGEN1181 Sensitive : C3	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials AGEN2034 + AGEN1181 Sensitive : C3
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials AGEN2034 + AGEN1181 Sensitive : C3	AGEN2034 + AGEN1181 Sensitive: C3 – Early Trials AGEN2034 + AGEN1181 Sensitive : C3